Mckinley Capital Management Increased By $753,312 Its Eagle Pharmaceuticals Co (EGRX) Position; Expeditors International Of Washington (EXPD) Has 1.04 Sentiment

February 11, 2018 - By Nellie Frank

Mckinley Capital Management Inc increased Eagle Pharmaceuticals Inc Co (EGRX) stake by 73.11% reported in 2017Q3 SEC filing. Mckinley Capital Management Inc acquired 12,768 shares as Eagle Pharmaceuticals Inc Co (EGRX)’s stock rose 7.49%. The Mckinley Capital Management Inc holds 30,233 shares with $1.80 million value, up from 17,465 last quarter. Eagle Pharmaceuticals Inc Co now has $847.70M valuation. The stock increased 1.32% or $0.74 during the last trading session, reaching $56.81. About 255,249 shares traded or 15.47% up from the average. Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has risen 79.40% since February 11, 2017 and is uptrending. It has outperformed by 62.70% the S&P500.

Expeditors International of Washington, Inc. provides logistics services. The company has market cap of $10.77 billion. The firm offers airfreight services, including air freight consolidation and forwarding; ocean freight and ocean services comprising ocean freight consolidation, direct ocean forwarding, and order management; customs brokerage, intra-continental ground transportation and delivery, and warehousing and distribution services; and customs clearance, purchase order management, vendor consolidation, time-definite transportation services, cargo insurance, and other logistics solutions. It has a 25.47 P/E ratio. It acts as a freight consolidator or as an agent for the airline, which carries the shipment.

Mcdonald Capital Investors Inc Ca holds 9.54% of its portfolio in Expeditors International of Washington, Inc. for 1.87 million shares. Tensile Capital Management Llc owns 626,015 shares or 7.13% of their US portfolio. Moreover, St. James Investment Company Llc has 5.46% invested in the company for 810,822 shares. The Nebraska-based America First Investment Advisors Llc has invested 4.9% in the stock. Marshfield Associates, a -based fund reported 1.18 million shares.

Analysts await Expeditors International of Washington, Inc. (NASDAQ:EXPD) to report earnings on February, 20. They expect $0.64 earnings per share, up 4.92% or $0.03 from last year’s $0.61 per share. EXPD’s profit will be $113.73 million for 23.68 P/E if the $0.64 EPS becomes a reality. After $0.66 actual earnings per share reported by Expeditors International of Washington, Inc. for the previous quarter, Wall Street now forecasts -3.03% negative EPS growth.

The stock increased 0.43% or $0.26 during the last trading session, reaching $60.62. About 1.37M shares traded or 26.43% up from the average. Expeditors International of Washington, Inc. (EXPD) has risen 10.45% since February 11, 2017 and is uptrending. It has underperformed by 6.25% the S&P500.

Mckinley Capital Management Inc decreased T Mobile Us Inc Co (NYSE:TMUS) stake by 93,933 shares to 585,677 valued at $36.11M in 2017Q3. It also reduced Unitedhealth Group Inc Co (NYSE:UNH) stake by 40,949 shares and now owns 120,617 shares. Apple Inc Co (NASDAQ:AAPL) was reduced too.

Among 4 analysts covering Eagle Pharma (NASDAQ:EGRX), 3 have Buy rating, 1 Sell and 0 Hold. Therefore 75% are positive. Eagle Pharma had 21 analyst reports since July 29, 2015 according to SRatingsIntel. Mizuho upgraded Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) rating on Thursday, November 3. Mizuho has “Buy” rating and $78 target. As per Sunday, November 5, the company rating was maintained by RBC Capital Markets. The firm has “Buy” rating given on Wednesday, December 9 by Mizuho. The stock of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has “Neutral” rating given on Monday, June 20 by Mizuho. The stock has “Buy” rating by RBC Capital Markets on Monday, October 2. As per Wednesday, November 2, the company rating was maintained by William Blair. The stock of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has “Buy” rating given on Wednesday, October 26 by Mizuho. On Wednesday, August 9 the stock rating was maintained by Piper Jaffray with “Buy”. Mizuho downgraded it to “Neutral” rating and $78 target in Wednesday, November 16 report. The stock of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has “Overweight” rating given on Wednesday, July 29 by Piper Jaffray.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>